2022
Persistent sensory changes and sex differences in transgenic mice conditionally expressing HIV-1 Tat regulatory protein
Toma W, Paris J, Warncke U, Nass S, Caillaud M, McKiver B, Ondo O, Bagdas D, Bigbee J, Knapp P, Hauser K, Damaj M. Persistent sensory changes and sex differences in transgenic mice conditionally expressing HIV-1 Tat regulatory protein. Experimental Neurology 2022, 358: 114226. PMID: 36096180, PMCID: PMC10053560, DOI: 10.1016/j.expneurol.2022.114226.Peer-Reviewed Original ResearchConceptsSensory neuropathyFemale miceHIV-1Tat expressionSensory nerve action potentialsIntraepidermal nerve fiber densityChronic HIV-1Persistent sensory changesPain-like behaviorsPeripheral sensory neuropathySevere chronic painDevelopment of neuropathyNerve fiber densityLumbar spinal cordDevelopment of hypersensitivityNerve action potentialsPrevious preclinical studiesDorsal root gangliaTNF-α expressionPPAR-α gene expressionTat regulatory proteinRole of TatHIV-1 TatSex differencesAllodynic responses
2020
Deficit in voluntary wheel running in chronic inflammatory and neuropathic pain models in mice: Impact of sex and genotype
Contreras KM, Caillaud M, Neddenriep B, Bagdas D, Roberts JL, Ulker E, White AB, Aboulhosn R, Toma W, Khalefa T, Adel A, Mann JA, Damaj MI. Deficit in voluntary wheel running in chronic inflammatory and neuropathic pain models in mice: Impact of sex and genotype. Behavioural Brain Research 2020, 399: 113009. PMID: 33181181, PMCID: PMC8961431, DOI: 10.1016/j.bbr.2020.113009.Peer-Reviewed Original ResearchConceptsNeuropathic pain modelChronic constriction injuryMechanical withdrawal thresholdPain modelStrains of miceWithdrawal thresholdDBA/2J miceVoluntary wheelChronic neuropathic pain modelPaclitaxel-treated miceVehicle-treated miceUnilateral intraplantar injectionLower mechanical thresholdsChronic pain reportQuality of lifeChemotherapy agent paclitaxelImpact of sexDifferent mouse strainsCCI miceCCI surgeryConstriction injuryIntraplantar injectionSham surgeryMale C57BL/6JNovel analgesicsConditional expression of HIV‐1 tat in the mouse alters the onset and progression of tonic, inflammatory and neuropathic hypersensitivity in a sex‐dependent manner
Bagdas D, Paris J, Carper M, Wodarski R, Rice A, Knapp P, Hauser K, Damaj M. Conditional expression of HIV‐1 tat in the mouse alters the onset and progression of tonic, inflammatory and neuropathic hypersensitivity in a sex‐dependent manner. European Journal Of Pain 2020, 24: 1609-1623. PMID: 32533878, PMCID: PMC7856573, DOI: 10.1002/ejp.1618.Peer-Reviewed Original ResearchConceptsHIV-1 TatSex-dependent mannerFemale miceMechanical hypersensitivityAdjuvant injectionThermal hypersensitivityNeurotoxic HIV-1 regulatory proteinComplete Freund's adjuvant injectionChronic constrictive nerve injuryHIV sensory neuropathyNeuropathic nociceptive behaviorMagnitude of inflammationFreund's adjuvant injectionPeripheral nervous systemHIV-1 regulatory proteinHIV-1 proteinsAbility of TatSex differencesSequel of eventsNeuropathic hypersensitivityTat miceNerve injuryFormalin injectionPeripheral neuropathySensory neuropathy
2019
Neuropathic insult increases the responsiveness to acetic acid in mice.
Gurdap C, Markwalter P, Neddenriep B, Bagdas D, Damaj M. Neuropathic insult increases the responsiveness to acetic acid in mice. Behavioural Pharmacology 2019, 30: 534-537. PMID: 31033524, PMCID: PMC6684379, DOI: 10.1097/fbp.0000000000000486.Peer-Reviewed Original ResearchConceptsChronic constriction injuryChronic neuropathic painNeuropathic painPlace aversionAcute visceral painVehicle-treated micePeripheral nerve injuryPlace aversion (CPA) testPaclitaxel-treated animalsMillions of patientsCCI miceConstriction injuryVisceral painCCI animalsSham miceAcute painNerve injuryControl miceSciatic nerveNeuropathic insultMale miceNociceptive modelsPaclitaxel treatmentPainPlace conditioningC57BL/6 substrain differences in inflammatory and neuropathic nociception and genetic mapping of a major quantitative trait locus underlying acute thermal nociception
Bryant C, Bagdas D, Goldberg L, Khalefa T, Reed E, Kirkpatrick S, Kelliher J, Chen M, Johnson W, Mulligan M, Damaj M. C57BL/6 substrain differences in inflammatory and neuropathic nociception and genetic mapping of a major quantitative trait locus underlying acute thermal nociception. Molecular Pain 2019, 15: 1744806918825046. PMID: 30632432, PMCID: PMC6365993, DOI: 10.1177/1744806918825046.Peer-Reviewed Original ResearchConceptsAcute thermal nociceptionThermal nociceptionNerve injuryNociceptive behaviorPain modalitiesB6N miceAdjuvant modelComplete Freund's adjuvant (CFA) modelChronic constrictive nerve injuryBaseline mechanical thresholdInflammatory nociceptive behaviorsInflammatory nociceptive stimulusStrain differencesFreund's adjuvant modelDifferent pain modalitiesHot plate testPreclinical pain modelsHot plate sensitivityNeuropathic nociceptionNociceptive markersPaw diameterMechanical hypersensitivityInflammatory painNeuropathic painPain model
2018
New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice
Bagdas D, Alkhlaif Y, Jackson A, Carroll FI, Ditre JW, Damaj MI. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice. Neuropharmacology 2018, 138: 72-79. PMID: 29860196, PMCID: PMC6054891, DOI: 10.1016/j.neuropharm.2018.05.025.Peer-Reviewed Original ResearchConceptsEffects of vareniclineNicotine withdrawal signsNicotine rewardΑ5 nAChRWithdrawal signsHigh doseKnockout miceΒ2-nAChRsNicotine withdrawal-induced hyperalgesiaAdministration of vareniclineWithdrawal-induced hyperalgesiaΑ7 knockout miceDose-related mannerNicotinic acetylcholine receptorsΑ5 knockout micePlace preference testVarenicline doseCessation treatmentNicotine withdrawalSomatic signsVareniclineΑ7 nAChRsMouse modelCPP testNicotinic subtypesMonoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy
Curry Z, Wilkerson J, Bagdas D, Kyte S, Patel N, Donvito G, Mustafa M, Poklis J, Niphakis M, Hsu K, Cravatt B, Gewirtz D, Damaj M, Lichtman A. Monoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy. Journal Of Pharmacology And Experimental Therapeutics 2018, 366: jpet.117.245704. PMID: 29540562, PMCID: PMC6038031, DOI: 10.1124/jpet.117.245704.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsApoptosisBenzodioxolesBiomarkersCarbamatesCell Line, TumorCell ProliferationChemokine CCL2Disease Models, AnimalDose-Response Relationship, DrugEnzyme InhibitorsHumansHyperalgesiaInflammationMaleMiceMonoacylglycerol LipasesNociceptionP38 Mitogen-Activated Protein KinasesPaclitaxelPhosphoproteinsPiperidinesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2SuccinimidesConceptsAntinociceptive effectPaclitaxel-induced mechanical allodyniaPaclitaxel-induced neuropathic painH460 non-small cell lung cancer cellsNon-small cell lung cancer cellsMonoacylglycerol lipaseMonocyte chemoattractant protein-1Chemotherapy-induced neuropathyPaclitaxel-induced allodyniaPain side effectsPrimary hydrolytic enzymesCell lung cancer cellsSpinal dorsal hornDorsal root gangliaChemoattractant protein-1Novel pharmacologic strategiesPaclitaxel-treated animalsNumerous rodent modelsLung cancer cellsPlace preference paradigmMonoacylglycerol lipase inhibitorsIntrinsic rewarding effectsPhospho-p38 MAPKMechanical allodyniaNeuropathic pain
2017
Nicotine prevents and reverses paclitaxel-induced mechanical allodynia in a mouse model of CIPN
Kyte S, Toma W, Bagdas D, Meade J, Schurman L, Lichtman A, Chen Z, Del Fabbro E, Fang X, Bigbee J, Damaj M, Gewirtz D. Nicotine prevents and reverses paclitaxel-induced mechanical allodynia in a mouse model of CIPN. Journal Of Pharmacology And Experimental Therapeutics 2017, 364: jpet.117.243972. PMID: 29042416, PMCID: PMC5738719, DOI: 10.1124/jpet.117.243972.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyPaclitaxel-induced mechanical allodyniaMechanical allodyniaPeripheral neuropathyMouse modelTreatment of CIPNLewis lung carcinoma tumor growthIntraepidermal nerve fiber lossPaclitaxel-induced peripheral neuropathyH460 non-small cell lung cancer cellsNon-small cell lung cancer cellsLung tumor cell proliferationNerve fiber dysfunctionNicotinic acetylcholine receptor subtypesCell lung cancer cellsChronic nicotine administrationNerve fiber lossChronic nicotine treatmentMale C57BL/6J miceAcetylcholine receptor subtypesLung cancer cellsProliferation of A549Receptor-mediated pathwayTumor cell proliferationCIPN treatmentEffects of paclitaxel on the development of neuropathy and affective behaviors in the mouse
Toma W, Kyte S, Bagdas D, Alkhlaif Y, Alsharari S, Lichtman A, Chen Z, Del Fabbro E, Bigbee J, Gewirtz D, Damaj M. Effects of paclitaxel on the development of neuropathy and affective behaviors in the mouse. Neuropharmacology 2017, 117: 305-315. PMID: 28237807, PMCID: PMC5489229, DOI: 10.1016/j.neuropharm.2017.02.020.Peer-Reviewed Original ResearchConceptsCancer chemotherapeutic drugsCancer patientsPreclinical modelsSide effectsAffective symptomsMajor dose-limiting side effectDose-limiting side effectChemotherapeutic drugsLight/dark box testNerve fiber dysfunctionPaclitaxel-treated miceProgression-free survivalSucrose preference testDepression-like behaviorOvarian cancer patientsSevere side effectsAnxiety-like behaviorPotential therapeutic interventionsEffect of paclitaxelAnhedonia-like stateDark box testCold allodyniaNeuropathic painNegative affective symptomsNociceptive effects
2014
Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice
Bagdas D, Muldoon P, Zhu A, Tyndale R, Damaj M. Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. Neuropharmacology 2014, 85: 67-72. PMID: 24859605, PMCID: PMC4106981, DOI: 10.1016/j.neuropharm.2014.05.006.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnxietyAryl Hydrocarbon HydroxylasesConditioning, PsychologicalCytochrome P450 Family 2Disease Models, AnimalDose-Response Relationship, DrugEnzyme InhibitorsHyperalgesiaMaleMecamylamineMethoxsalenMice, Inbred ICRMotor ActivityNicotineNicotinic AgonistsNicotinic AntagonistsRewardSeverity of Illness IndexSubstance Withdrawal SyndromeTobacco Use DisorderConceptsNicotine plasma levelsWithdrawal signsPlasma levelsAdministration of methoxsalenEffect of methoxsalenNicotine dependence behaviorsNicotine replacement therapyChronic nicotine infusionDependence-related behaviorsDrug elimination ratePlace preference testMetabolism of nicotineReward-like propertiesLack of enhancementSpontaneous withdrawalNicotine withdrawalReplacement therapyNicotine preferenceLow doseHigh doseNicotine infusionMouse CYP2A5CPP testActive nicotineNicotine levels
2013
Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain.
Kanat O, Bagdas D, Ozboluk H, Gurun M. Preclinical evidence for the antihyperalgesic activity of CDP-choline in oxaliplatin-induced neuropathic pain. JBUON 2013, 18: 1012-8. PMID: 24344031.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesicsAnimalsCytidine Diphosphate CholineDisease Models, AnimalDose-Response Relationship, DrugGABA-B Receptor AntagonistsHyperalgesiaInjections, IntraventricularMaleNeuralgiaNeurotransmitter Uptake InhibitorsNicotinic AntagonistsOrganoplatinum CompoundsOxaliplatinPain ThresholdRatsRats, Sprague-DawleyTime FactorsConceptsAntihyperalgesic effectNeuropathic painCDP-cholineNonselective muscarinic receptor antagonist atropineNonselective opioid receptor antagonist naloxoneRat paw pressure testReceptor antagonist CGP 35348Muscarinic receptor antagonist atropineNicotinic receptor antagonist mecamylamineOpioid receptor antagonist naloxoneOxaliplatin-induced neuropathic painCholine uptake inhibitor hemicholinium-3Induction of neuropathyAntagonist CGP 35348Paw pressure testGamma-amino butyric acidNicotinic acetylcholine receptorsCGP 35348Neuropatic painMechanical hyperalgesiaAntagonist atropineTime-dependent mannerPreclinical evidenceAntagonist naloxoneAntihyperalgesic activity
2012
Antihyperalgesic activity of chlorogenic acid in experimental neuropathic pain
Bagdas D, Cinkilic N, Ozboluk H, Ozyigit M, Gurun M. Antihyperalgesic activity of chlorogenic acid in experimental neuropathic pain. Journal Of Natural Medicines 2012, 67: 698-704. PMID: 23203628, DOI: 10.1007/s11418-012-0726-z.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesicsAnimalsChlorogenic AcidHyperalgesiaMaleMotor ActivityNeuralgiaRatsRats, Sprague-DawleySciatic NerveConceptsChronic constrictive nerve injuryNeuropathic painAntihyperalgesic activityPeripheral neuropathic pain modelExperimental neuropathic painNeuropathic pain modelRota-rod testNovel potential therapeutic optionPotential therapeutic optionStrong therapeutic effectLatency of ratsChlorogenic acidAntihyperalgesic effectMechanical hyperalgesiaNerve injuryPain modelChronic administrationInflammatory cascadeTherapeutic optionsHistopathological changesInflammatory processTherapeutic effectAnalgesic activityPainNervous system
2011
The antihyperalgesic effect of cytidine-5′-diphosphate-choline in neuropathic and inflammatory pain models
Bagdas D, Sonat F, Hamurtekin E, Sonal S, Gurun M. The antihyperalgesic effect of cytidine-5′-diphosphate-choline in neuropathic and inflammatory pain models. Behavioural Pharmacology 2011, 22: 589-598. PMID: 21836465, DOI: 10.1097/fbp.0b013e32834a1efb.Peer-Reviewed Original ResearchConceptsNeuropathic pain modelAntihyperalgesic effectPain modelChronic constriction injury-induced neuropathic pain modelNonselective muscarinic receptor antagonist atropineNonselective opioid receptor antagonist naloxoneΓ-aminobutyric acid B receptorsNicotinic ACh receptor antagonistsReceptor antagonist CGP 35348Muscarinic receptor antagonist atropineNicotinic receptor antagonist mecamylamineOpioid receptor antagonist naloxoneCholine uptake inhibitor hemicholinium-3CDP-cholineEffect of intracerebroventricularlyAntagonist CGP 35348Central opioid receptorsInflammatory pain modelACh receptor antagonistNicotinic ACh receptorsCGP 35348Mechanical hyperalgesiaNeuropathic painAntagonist atropineAntagonist naloxone